Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Company announcement – No. 22 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, October 17, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 16 October 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 15 October 2025, Van Herk Investments B.V. ...
A director at Television Francaise(TF1) bought 44,000 shares at 8.618EUR and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Les 3 acteurs évoluent dans un environnement sous contrainte, à l’origine de résultats en fort repli et d’incertitudes sur le timing de la reprise de cycle. Nous révisons en baisse nos estimations (-8% sur le ROC 2025/27 en moyenne). Notre hiérarchie privilégie la qualité des bilans, l’exposition à l’Europe et la communication transparente. Cela nous amène à mettre en avant Manitou (Surperformance ; OC 25 €) vs Exel Industries (Neutre ; OC 40 €) et Haulotte (Sous-performance, OC 1.15 € vs 2 €).
The three players are operating in a tough environment, causing their results to tumble and making it difficult to predict when the cycle will pick up again. We are lowering our expectations, with 2025-27 underlying operating profit estimates cut by 8% on average. In our industry hierarchy, we are leaning toward quality balance sheets, exposure to Europe and guidance disclosure; this is why we favour Manitou (Outperform, TP € 25) over Exel Industries (Neutral, TP € 40) and Haulotte (Underperform...
Total number of shares and voting rights in Zealand Pharma as of September 30, 2025 Company announcement – No. 21 / 2025 Total number of shares and voting rights in Zealand Pharma as of September 30, 2025 Copenhagen, Denmark, September 30, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end o...
IDI enters a new gear EARNINGS/SALES RELEASES After a period of measured restraint, IDI is shifting into a more active phase. Investment activity has picked up sharply, with carefully chosen deals that demonstrate discipline and foresight rather than chasing volume. CDS/S4BT, Intesoft, Forsk, and targeted bolt-ons show that IDI is not deploying capital for the sake of it. This is portfolio engineering with precision, optionality, and the compounding power of a firm that knows when to act and w...
Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations Press release – No. 14 / 2025 Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations Copenhagen, Denmark, September 24, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Rachel James-Owens as Vice President, Corporate Communications & Media Relations. Rachel brings over 20 years of global...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.